TrialNature medicine2024

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

Arun J Sanyal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.